Bayesian methods for the design and interpretation of clinical trials in very rare diseases

Statistics in Medicine

Volumn 33, Issue 24, 2014, Pages 4186-4201

  Hampson, Lisa V ^a   Whitehead, John ^a   Eleftheriou, Despina ^b   Brogan, Paul ^b  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Allocation ratio; Bayesian model; Expert opinion; Prior elicitation; Prior power; Rare diseases

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ANCA ASSOCIATED VASCULITIS; ARTICLE; BAYES THEOREM; BLADDER DISEASE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; HUMAN; INFECTION; INFERTILITY; MATHEMATICAL MODEL; NAUSEA; NEOPLASM; OUTCOME ASSESSMENT; POLYARTERITIS NODOSA; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; REMISSION; SAMPLE SIZE; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS; ANALOGS AND DERIVATIVES; CHILD; CLINICAL TRIAL (TOPIC); METHODOLOGY; PROCEDURES; RARE DISEASES; STATISTICAL MODEL; TREATMENT OUTCOME;

BAYES THEOREM; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; MODELS, STATISTICAL; MYCOPHENOLIC ACID; POLYARTERITIS NODOSA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; REMISSION INDUCTION; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84908042854     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6225     Document Type: Article

References (38)

1. European Medicines Agency. Guideline on clinical trials in small populations, 2006. http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2009/09/WC500003615.pdf, Accessed 11 June 2014.
2. Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. British Medical Journal 1995; 311(7020):1621-1625.
3. Billingham L,Malottki K, Steven N. Small sample sizes in clinical trials: a statistician's perspective. Clinical Investigation 2012; 2(7):655-657.
4. Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ. Summarizing historical information on controls in clinical trials. Clinical Trials 2010; 7(1):5-18.
5. Schmidli H, Wandel S, Neuenschwander B. The network meta-analytic-predictive approach to non-inferiority trials. Statistical Methods in Medical Research 2011; 22(2):219-240.
6. Gsteiger S, Neuenschwander B, Mercier F, Schmidli H. Using historical control information for the design and analysis of clinical trials with overdispersed count data. Statistics in Medicine 2013; 32(21):3609-3622.
7. Ibrahim JG, Chen M-H. Power prior distributions for regression models. Statistical Science 2000; 15(1):46-60.
8. Tan S-B, Dear KBG, Bruzzi P, Machin D. Strategy for randomised clinical trials in rare cancers. British Medical Journal 2003; 327(7405):47-49.
9. Goodman SN, Sladky JT. A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barré. Clinical Trials 2005; 2(4):305-310.
10. Schoenfeld DA, Zheng H, Finkelstein DM. Bayesian design using adult data to augment pediatric trials. Clinical Trials 2009; 6(4):297-304.
11. Hogarth RM. Cognitive processes and the assessment of subjective probability distributions. Journal of the American Statistical Association 1975; 70(350):271-289.
12. Garthwaite PH, Kadane JB, O'Hagan A. Elicitation. Journal of the American Statistical Association 2005; 100(470): 680-700.
13. Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Feldman BM. Methods to elicit beliefs for Bayesian priors: a systematic review. Journal of Clinical Epidemiology 2010; 63(4):355-369.
14. Kinnersley N, Day S. Structured approach to the elicitation of expert beliefs for a Bayesian-designed clinical trial: a case study. Pharmaceutical Statistics 2013; 12(2):104-113.
15. Kadane JB, Wolfson LJ. Experiences in elicitation. The Statistician 1998; 47(1):3-19.
16. O'Hagan A. Eliciting expert beliefs in substantial practical applications. The Statistician 1998; 47(1):21-35.
17. O'Hagan A, Buck CE, DaneshkhahA, Eiser JR,Garthwaite PH, Jenkinson DJ,Oakley JE, RakowT. Uncertain Judgements: Eliciting Experts' Probabilities. Wiley: Chichester, UK, 2006.
18. Chaloner K, Rhame FS. Quantifying and documenting prior beliefs in clinical trials. Statistics in Medicine 2001; 20(4): 581-600.
19. Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Hawker GA, Feldman BM. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. The Journal of Rheumatology 2011; 38(3):462-469.
20. Tan S-B, Chung Y-FA, Tai B-C, Cheung Y-B, Machin D. Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma. Controlled Clinical Trials 2003; 24(2): 110-121.
21. Hiance A, Chevret S, Levy V. A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trial. Journal of Clinical Epidemiology 2009; 62(4):431-437.
22. Eales JD, Jennison C. An improved method for deriving optimal one-sided group sequential tests. Biometrika 1992; 79(1):13-24.
23. Whitehead J. The Design and Analysis of Sequential Clinical Trials Second Edition. Wiley: Chichester, UK, 1997.
24. Pravitsitthikul N, Willis NS, Hodson EM, Craig JC. Non-corticosteroid immunosuppressive medications for steroidsensitive nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD002290.
25. Hampson LV, Whitehead J, Eleftheriou D, Tudur-Smith C, Jones R, Jayne D, Hickey H, MYPAN Vasculitis Group, Brogan PA. Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa. Submitted.
26. Kadane JB, Dickey JM, Winkler RL, Smith WS, Peters SC. Interactive elicitation of opinion for a normal linear model. Journal of the American Statistical Association 1980; 75(372):845-854.
27. R Core Team. R: A Language and Environment For Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2013.
28. RStudio and Inc. shiny: web application framework for R. R package version 0.7.099., 2013. http://www.rstudio.com/shiny/, Accessed 16 September 2013.
29. Delbecq AL, van de Ven AH. A group process model for problem identification and program planning. The Journal of Applied Behavioral Science 1971; 7(4):466-492.
30. Morita S, Thall PF, Müller P. Determining the effective sample size of a parametric prior. Biometrics 2008; 64(2):595-602.
31. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society Series A 2009; 172(1):137-159.
32. Pocock S. The combination of randomized and historical controls in clinical trials. Journal of Chronic Disease 1976; 29(3):175-88.
33. Whitehead J, Valdes-Marquez E, Johnson P, Graham G. Bayesian sample size for exploratory clinical trials incorporating historical data. Statistics in Medicine 2008; 27(13):2307-2327.
34. Whitehead J, Brunier H. Bayesian decision procedures for dose determining experiments. Statistics in Medicine 1995; 14(9):885-893.
35. Whitehead J, Patterson S,Webber D, Francis S, Zhou Y. Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics 2001; 2(1):47-61.
36. Dalal SR, Hall WJ. Approximating priors by mixtures of natural conjugate priors. Journal of the Royal Statistical Society, Series B 1983; 45(2):278-286.
37. Schmidli H, Gsteiger S, Roychoudhury S, O'Hagan A, Speigelhalter D, Neuenschwander B. Robust meta-analyticpredictive priors in clinical trials with historical controlinformation. Submitted.
38. Welton NJ, Sutton AJ, Cooper NJ, Abrams KR, Ades AE. Evidence Synthesis for Decision Making in Healthcare. Wiley: Chichester, UK, 2012.